Flagship's $3.37bn Fund To Grow First-In-Category Firms
Also Building Preemptive Medicine Division
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
You may also be interested in...
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.
After slightly more than two years as second-in-command, Abernethy tells the Pink Sheet she’s leaving FDA because the initiatives on which she was focused were starting to develop their own momentum. Abernethy, who also serves as the agency’s acting chief information officer, worked to modernize the FDA’s information technology infrastructure and data capabilities while also exploring ways to confidently use real-world data to support regulatory decision-making.